Literature DB >> 11167218

Latanoprost-induced increase of tyrosinase transcription in iridial melanocytes.

J Stjernschantz1, A Ocklind, P Wentzel, S Lake, D N Hu.   

Abstract

PURPOSE: Latanoprost, the active principle of Xalatan eye drops, has been shown to cause increased iridial pigmentation as a side-effect in some patients. The purpose of the present study was to investigate whether latanoprost affects tyrosinase, the rate limiting enzyme in melanogenesis, at the gene transcription level in the iridial melanocytes.
METHODS: Four cynomolgus monkeys were treated unilaterally with 3 or 11 microg latanoprost once daily for 10 days. The contralateral eye received the vehicle only. Tyrosinase mRNA was visualized by in situ hybridization using radio-labelled riboprobes. The transcription of tyrosinase was also studied in vitro using cultivated human iridial melanocytes. Tyrosinase RNA was quantified by Northern blotting.
RESULTS: In the monkeys transcription of tyrosinase was found to be increased in iridial melanocytes of the treated eyes compared to the control eyes. Increased transcription of tyrosinase was in addition found in the iridial pigment epithelium and in melanocytes of the anterior choroid. Latanoprost was also found to increase the transcription of tyrosinase in melanocytes isolated from at least one human eye.
CONCLUSIONS: Although the tyrosinase enzyme has to undergo complex post-translational modification to become biologically active, which we have not studied, it appears that latanoprost treatment may increase the transcription of the tyrosinase gene in some individuals, consistent with increased melanogenesis in the iridial melanocytes leading to darker eye colour.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11167218     DOI: 10.1034/j.1600-0420.2000.078006618.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  4 in total

1.  A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides.

Authors:  Daniel M Albert; Ronald E Gangnon; Hans E Grossniklaus; W Richard Green; Soesiawati Darjatmoko; Amol D Kulkarni
Journal:  Arch Ophthalmol       Date:  2008-05

2.  Latanoprost-induced changes in the iris and trabeculum: an electron-microscopic morphological study.

Authors:  Nilgun Yildirim; Afsun Sahin; Selcuk Kara; Cengiz Baycu
Journal:  Int Ophthalmol       Date:  2009-01-13       Impact factor: 2.031

Review 3.  Latanoprost : an update of its use in glaucoma and ocular hypertension.

Authors:  Caroline M Perry; Jane K McGavin; Christine R Culy; Tim Ibbotson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

4.  Effects of sustained daily latanoprost application on anterior chamber anatomy and physiology in mice.

Authors:  Laura M Dutca; Danielle Rudd; Victor Robles; Anat Galor; Mona K Garvin; Michael G Anderson
Journal:  Sci Rep       Date:  2018-08-30       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.